Myriad Genetics (MYGN) Reports Q1 EPS of 24c
Tweet Send to a FriendGet Alerts MYGN Hot Sheet
Trade MYGN Now!
Myriad Genetics, Inc. (Nasdaq: MYGN) reports Q1 EPS of $0.24, 1 cent better than the analyst estimate of $0.23. Revenue for the quarter was $91.9 million, which compares to the estimate of $92.76 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Pandora Media (P) Reports In-Line Q1 EPS, Revenue & Guidance Beat
- Pandora (P) Pops Higher on Q1 Results; Expands Listener Base by 2.5M Subs
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
